ZNF865 (BLST): A novel regulator of DNA damage, cellular senescence and age-related Intervertebral disc degeneration 

Introduction 

Intervertebral disc degeneration (IVDD) is a major cause of chronic low back pain, particularly among ageing populations. Intervertebral discs are fibrocartilaginous structures located between adjacent vertebral bodies that provide flexibility, distribute mechanical loads and facilitate spinal movement. Ageing, genetic predisposition, mechanical loading and impaired nutrient transport contribute to progressive disc degeneration. These changes are accompanied by extracellular matrix breakdown, loss of cellular activity and increased production of inflammatory mediators. 

Cellular senescence has emerged as an important mechanism underlying age-related musculoskeletal disorders. Senescent cells undergo stable cell-cycle arrest and develop a senescence-associated secretory phenotype (SASP), characterized by the secretion of pro-inflammatory cytokines, chemokines and matrix-degrading enzymes. Accumulation of senescent cells within the intervertebral disc can promote inflammation, extracellular matrix degradation and tissue dysfunction. DNA damage is another important contributor to cellular senescence, although the molecular regulators connecting DNA damage with disc degeneration remain incompletely understood.  

ZNF865 (BLST): Identification and functional significance 

ZNF865, also known as BLST, is a previously uncharacterized zinc finger protein that has recently emerged as a potential regulator of cellular homeostasis. It belongs to the C2H2 zinc finger protein family and contains multiple zinc finger domains and transcriptional activation domains, suggesting a possible role in transcriptional regulation. Before the recent investigation, its biological functions were largely unknown. 

The research team led by Robby D. Bowles at the University of Utah investigated the role of ZNF865 using CRISPR-based gene modulation approaches. The study demonstrated that ZNF865 expression was reduced in aged and degenerated human and mouse intervertebral disc samples. Furthermore, patient-derived nucleus pulposus cells from degenerated discs exhibited lower ZNF865 expression and protein levels than cells obtained from healthy discs. These observations suggested an association between reduced ZNF865 expression, DNA damage and cellular senescence in disc degeneration.1 

To investigate its functional role, researchers employed CRISPR activation (CRISPRa) to increase ZNF865 expression and CRISPR interference (CRISPRi) to suppress its expression. Downregulation of ZNF865 in healthy human nucleus pulposus cells induced cellular senescence, increased DNA damage and promoted the expression of SASP-associated factors. Conversely, restoring ZNF865 expression in degenerated human nucleus pulposus cells reduced senescence markers, DNA damage and inflammatory mediators. The intervention also improved extracellular matrix (ECM) anabolism and restored chromatin accessibility and gene expression patterns towards a healthier cellular state.2 

These findings suggest that ZNF865 is involved in maintaining genomic stability and regulating cellular processes associated with tissue ageing. Importantly, the ability to improve the phenotype of degenerated human disc cells following ZNF865 restoration provides a potential therapeutic direction beyond conventional approaches targeting inflammation or pain. 

Role of cellular senescence and DNA damage in disc degeneration 

Cellular senescence is characterized by stable cell-cycle arrest, accompanied by changes in cellular metabolism, gene expression and secretory activity. Although senescence initially serves as a protective mechanism against the propagation of damaged cells, the persistent accumulation of senescent cells can contribute to chronic inflammation and tissue dysfunction.2,3 

Senescent cells develop a SASP characterized by increased secretion of inflammatory cytokines, chemokines, matrix metalloproteinases (MMPs) and growth factors. These mediators alter the surrounding tissue microenvironment, promote ECM degradation and impair tissue repair.4 

In the intervertebral disc, ageing and mechanical stress contribute to DNA damage, oxidative stress and progressive cellular senescence. Previous studies have demonstrated increased senescence-associated markers in human degenerative discs, supporting the involvement of cellular senescence in IVDD.5,6 Furthermore, senescent nucleus pulposus cells exhibit reduced regenerative capacity and increased production of inflammatory and catabolic mediators, contributing to deterioration of disc architecture. 

The recent ZNF865 study provides additional insight into this relationship by identifying a potential molecular regulator linking DNA damage, senescence and disc degeneration. ZNF865 restoration reduced the expression of several SASP-associated mediators, including IL-1, IL-6, TNF-α, IL-8, MMP-1, MMP-3, MMP-12, nerve growth factor (NGF) and vascular endothelial growth factor (VEGF). These changes suggest that ZNF865 may influence both inflammatory signalling and ECM homeostasis.1 

Therapeutic implications: Targeting ZNF865 and cellular senescence 

The identification of ZNF865 provides a potential direction for developing therapeutic strategies targeting the molecular mechanisms of disc ageing. Unlike conventional treatments that primarily address pain and inflammation, restoring ZNF865 expression may help improve the functional characteristics of degenerated disc cells. 

Previous experimental studies have explored senolytic approaches to eliminate senescent cells and reduce their detrimental effects on disc tissue. Cherif et al. demonstrated that curcumin and o-vanillin exhibit senolytic activity in human intervertebral disc cells, reducing senescence-associated characteristics.7 In another study, treatment with RG-7112 and o-vanillin reduced SASP expression and improved matrix homeostasis in human degenerative disc samples.8 

Similarly, Novais et al. demonstrated that long-term administration of dasatinib and quercetin reduced senescence markers, preserved disc cellularity and improved disc tissue architecture in ageing mice.9 These findings support the therapeutic potential of targeting cellular senescence in IVDD. 

However, ZNF865 restoration represents a potentially different therapeutic approach. Rather than eliminating senescent cells, it may help restore cellular function by reducing DNA damage and senescence-associated changes. This distinction is important because cellular reprogramming and senolytic strategies target different aspects of the senescence process. 

Broader implications and future research 

The implications of ZNF865 may extend beyond intervertebral disc degeneration. The protein is widely expressed across different tissues, suggesting that its role in maintaining genomic stability may be relevant to other age-related disorders. DNA damage and cellular senescence are also implicated in neurodegenerative diseases, pulmonary fibrosis, osteoarthritis and cancer.2,10 

Enhancing ZNF865 activity could potentially improve DNA damage responses and cellular function in other tissues. However, its role in cancer requires careful investigation because cellular senescence also acts as a tumour-suppressive mechanism by preventing the proliferation of damaged cells. Therefore, the consequences of manipulating ZNF865 may differ depending on the tissue and disease context. 

The current evidence is primarily based on cellular experiments and preclinical animal models. The safety, delivery, long-term effects and tissue-specific consequences of ZNF865 modulation remain unclear. Further studies are required to establish the precise molecular mechanisms through which ZNF865 regulates DNA repair, chromatin accessibility and cellular senescence. In particular, the feasibility of targeted CRISPR-based delivery to intervertebral disc cells requires investigation. 

Conclusion 

ZNF865 (BLST) represents a newly characterized regulator of DNA damage, cellular senescence and intervertebral disc homeostasis. Its restoration reduced senescence-associated changes, inflammatory mediators and DNA damage while improving ECM-related cellular functions in experimental models. These findings provide a potential foundation for developing therapies targeting the molecular mechanisms of age-related disc degeneration. Nevertheless, further preclinical validation and clinical investigations are necessary before ZNF865-based interventions can be considered therapeutic options for patients with degenerative disc disease. 

References 

  1. Lewis C, Levis H, Holbrook J, Polaski JT, Jacobsen TD, Mizels J, et al. ZNF865 (BLST) a novel regulator of DNA damage and cell senescence in back pain. Aging Cell. 2026;25(10):e70754. 
  2. Huang W, Hickson LJ, Eirin A, Kirkland JL, Lerman LO. Cellular senescence: the good, the bad and the unknown. Nat Rev Nephrol. 2022;18(10):611–627. 
  3. Roberts S, Evans EH, Kletsas D, Jaffray DC, Eisenstein SM. Senescence in human intervertebral discs. Eur Spine J. 2006;15(Suppl 3):S312–316. 
  4. Coppé JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99–118. 
  5. Gruber HE, Ingram JA, Norton HJ, Hanley EN Jr. Senescence in cells of the aging and degenerating intervertebral disc: immunolocalization of senescence-associated beta-galactosidase in human and sand rat discs. Spine (Phila Pa 1976). 2007;32(3):321–327. 
  6. Wang F, Cai F, Shi R, Wang XH, Wu XT. Aging and age related stresses: a senescence mechanism of intervertebral disc degeneration. Osteoarthritis Cartilage. 2016;24(3):398–408. 
  7. Cherif H, Bisson DG, Jarzem P, Weber M, Ouellet JA, Haglund L. Curcumin and o-vanillin exhibit evidence of senolytic activity in human IVD cells in vitro. J Clin Med. 2019;8(4):433. 
  8. Cherif H, Bisson DG, Mannarino M, Rabau O, Ouellet JA, Haglund L. Senotherapeutic drugs for human intervertebral disc degeneration and low back pain. eLife. 2020;9:e54693. 
  9. Novais EJ, Tran VA, Johnston SN, Darris KR, Roupas AJ, Sessions GA, et al. Long-term treatment with senolytic drugs dasatinib and quercetin ameliorates age-dependent intervertebral disc degeneration in mice. Nat Commun. 2021;12:5213. 
  10. Feng C, Liu H, Yang M, Zhang Y, Huang B, Zhou Y. Disc cell senescence in intervertebral disc degeneration: causes and molecular pathways. Cell Cycle. 2016;15(13):1674–1684.

 

Don’t miss our updates!

We don’t spam! Read our [link]privacy policy[/link] for more info.

Leave a Reply